openPR Logo
Press release

Doxorubicin Market Competitive Landscape Analysis with Forecast by 2025

03-06-2018 03:32 PM CET | Health & Medicine

Press release from: Transparency Market Research

/ PR Agency: Transparency Market Research
Doxorubicin Market Competitive Landscape Analysis with

Doxorubicin is the generic drug name for anti-cancer chemotherapy drug Adriamycin and Rubex. Doxorubicin is an anthracycline antibiotic and belongs to the group of anti-cancer medication known as antineoplastic and is made from the natural product produced by bacterium Streptomyces peucetius var. caesius. It is used for the treatment of different types of cancer including breast, stomach, ovary, bone, testicles, bladder, lung, soft tissue, osteogenic sarcoma, Wilms’ tumor, and Hodgkin’s and non-Hodgkin’s lymphomas. It is also used less commonly in the treatment of squamous cell carcinomas of the head and neck.

Vagina and cervix, refractory multiple myeloma, and neuroblastoma. Doxorubicin inhibits and or slows the rate of proliferation of cancerous cells by intercalating between the base pairs in the DNA helix, thereby preventing DNA replication and inhibiting protein synthesis. This medication is available in injection solution and lyophilized powder form and is administered intravenously either through peripheral inserted central line catheters (PICC) or central venous catheters (CVC). The dosage of this medication depends on the type and severity of cancer, and type of other medication used during treatments and is most commonly scheduled at 21 days of every dosage.

Download Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=26138

The global doxorubicin market is anticipated to expand at a higher growth rate owing to increasing prevalence of cancer patients worldwide. According to the WHO, cancer is the leading cause of death globally, accounting 8.8 million deaths in 2015. The number of new cases is expected to increase by 70% in the next two decades. The global market for this drug is also expected to be driven by increasing use in the treatment of HIV-associated Kaposi sarcoma. HIV-associated Kaposi sarcoma has markedly increased in countries in Africa and the West in the last two decades.

On the other hand, doxorubicin medication can cause life threatening conditions such as heart failure during therapy or sometimes after months or years after treatment. Additionally, it can cause side effects such as nausea, vomiting, diarrhea, loss of appetite, and reddish urine after one to two days of treatment. These side effects, specifically cardio toxicity, imposes a limitation on the use of doxorubicin and creates an opportunity for development of lipid based (liposome) formulations with improved therapeutic index of conventional doxorubicin.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=26138

The global doxorubicin drug market has been segmented based on drug formulation, type of cancer, distribution channel, and region. In terms of drug formulation, the market has been segmented into lyophilized powder and doxorubicin injection. It is administered through the vein either peripherally or through central venous catheter. Based on type of cancer, the market has been segmented into lung cancer, Hodgkin’s and non-Hodgkin’s cancer, breast cancer, prostate cancer, ovary cancer, stomach cancer, leukemia, and others.

Lung and breast cancer are expected to be major segments of the global doxorubicin market. This medication is available in hospital pharmacy, retail pharmacy, and online pharmacy. Of these distribution channels, hospital pharmacy is projected to be the key segment during the forecast period.

Obtain Report Details @ https://www.transparencymarketresearch.com/doxorubicin-market.html

In terms of region, the global doxorubicin market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Europe is anticipated to dominate the global doxorubicin market owing to highest number of cancer patients and favorable medical reimbursement policies. North America is the second leading market for doxorubicin. Asia Pacific is projected to be the fastest growing market during the forecast period driven by increasing rate of diagnosis of cancer patients and improving health care accessibility and infrastructure.

Key players operating in the global doxorubicin market are Pfizer, Inc., Johnson & Johnson, Accord Healthcare, Novartis AG, Thymoorgan Pharmazie GmbH, Sun Pharmaceutical Industries Ltd., Allergan, Inc., Meiji Seika Pharma Co., Merrimack Pharmaceuticals, Inc., and Dr. Reddy’s Laboratories Ltd., among others.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Doxorubicin Market Competitive Landscape Analysis with Forecast by 2025 here

News-ID: 966928 • Views: 154

More Releases from Transparency Market Research

Voltage Detectors Market – Evolving Technology Trends and Industry SWOT Analys …
The global voltage detectors market includes large number of players. Some of the key players are Texas Instruments, Toshiba, ROHM Semiconductor Sharp Microelectronics, Analog Devices Inc., STMicroelectronics, ON Semiconductor, Torex Semiconductor, Taiwan Semiconductor and Seiko Instruments. Browse Our Report @ https://www.transparencymarketresearch.com/voltage-detectors-market.html Voltage Detector is a testing equipment generally used to determine the existence or absence of an electrical charge in an object. It is highly suggested for conditions where power issues exist.
Switched Capacitor Filters Market : Key Segments, Maket Insights, Regional Outlo …
Major players in the global switched capacitor filters market are Texas Instruments Incorporated, Analog Devices, Inc., Maxim Integrated, Inc., Siemens AG, Eaton Corporation, and among others. Browse Our Report @ https://www.transparencymarketresearch.com/switched-capacitor-filters-market.html A switched capacitor filter is an active filter based on the consideration that a switching of capacitors between two circuit nodes at an adequately high rate that is equivalent to a resistor connecting these two nodes. The switched capacitor filters are
Current Calibrator Market : Recent Industry Developments And Growth Strategies A …
Key players operating in the global current calibrator market include Valhalla Scientific, Rotek Inc., Time Electronics, PCE Instruments, Martel Electronics, AOIP Instrumentation, Extech Instruments, Yogokawa Test & Measurement Corporation, Extech Instruments, REED Instruments, Fluke Corporation, and others. These players are actively focusing on organic and inorganic growth strategies in order to gain a competitive advantage in the market. Some of the important strategies adopted by the leading players in the
Damp Meter Market – Outlook by Responsible Drivers, Restraints, Demand
Key players operating in the global damp meter market include PCE Instrument, Delmhorst Instrument Co., GENERAL TOOLS & INSTRUMENTS LLC, FLIR Systems, Inc. designs, Panomex Inc., These players are actively focusing on organic and inorganic growth strategies in order to gain a competitive advantage in the market. Some of the important strategies adopted by the leading players in the global market are collaborations, partnerships, agreements, and new product launches. The

All 5 Releases


More Releases for Doxorubicin

Global Doxorubicin Market Insights, Forecast
Doxorubicin is a kind of antitumor antibiotics, can inhibit the synthesis of RNA and DNA, RNA in the strongest inhibitory effect. Doxorubicin has an effect on a wide variety of tumor, belongs to the cycle non-specific drug, have all sorts of growth cycle of tumor cells to kill.it's given by injection into a vein. The global Doxorubicin market is valued at 910 million US$ in 2018 and will reach 1410
Doxorubicin Market Report Explored in Latest Research 2025
Doxorubicin is the generic drug name for anti-cancer chemotherapy drug Adriamycin and Rubex. Doxorubicin is an anthracycline antibiotic and belongs to the group of anti-cancer medication known as antineoplastic and is made from the natural product produced by bacterium Streptomyces peucetius var. caesius. Request Brochure- https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=26138 It is used for the treatment of different types of cancer including breast, stomach, ovary, bone, testicles, bladder, lung, soft tissue, osteogenic sarcoma, Wilms’ tumor, and Hodgkin’s
Doxorubicin Market to Reflect Steady Growth Rate by 2024
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). Anthracycline especially doxorubicin has been the mainstay of cancer treatment since many years. Doxorubicin also known as doxorubicin hydrochloride is an antibiotic belonging to class of medication known as anthracycline antibiotics, and is the first liposomal encapsulated anticancer drug to receive clinical approval and is used in the
Doxorubicin Market Highly Favorable to the Growth Rate by 2024
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). Anthracycline especially doxorubicin has been the mainstay of cancer treatment since many years. Doxorubicin also known as doxorubicin hydrochloride is an antibiotic belonging to class of medication known as anthracycline antibiotics, and is the first liposomal encapsulated anticancer drug to receive clinical approval and is used in the
Doxorubicin Market to Witness an Outstanding Growth by 2024
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). Anthracycline especially doxorubicin has been the mainstay of cancer treatment since many years. Doxorubicin also known as doxorubicin hydrochloride is an antibiotic belonging to class of medication known as anthracycline antibiotics, and is the first liposomal encapsulated anticancer drug to receive clinical approval and is used in the
Doxorubicin Market to Witness Widespread Expansion During 2016 - 2024
It is less commonly used in treatment of squamous cell carcinomas of head and neck, cervix and vagina, carcinomas of testes and prostate. The drug kills the cancerous cells in several ways including intercalation between DNA pairs thereby preventing replication of cancer cells, DNA strand breakage and inhibition with enzyme topoisomerase II. Doxorubicin is marketed either in the powdered or in solution form and is administered intravenously every 21 to